1. A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN'S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE. (15th March 2019) Authors: Panaccione, R; Colombel, J; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W; Skup, M; D'Haens, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 2(2019)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP065 Long-term cost-effectiveness of tight control for Crohn's disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial. (16th January 2018) Authors: Panaccione, R; Colombel, J -F; Bossuyt, P; Baert, F; Vanasek, T; Danalioglu, A; Novacek, G; Armuzzi, A; Reinisch, W; Johnson, S; Buessing, M; Neimark, E; Petersson, J; Robinson, A M; Thakkar, R B; Lee, W -J; Skup, M; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S074 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗